AstraZeneca reports strong progress with cancer drugs ahead of results

Drugmaker poised to file AZD9291 for lung cancer for US approval, while FDA grants orphan drug status for eye cancer treatment

AstraZeneca has received a double boost after publishing promising data on a key experimental lung cancer pill while a rare eye cancer treatment moved a step closer to regulatory approval in the US.

The Anglo-Swedish drugmaker expects to file AZD9291 for lung cancer for US approval in the coming weeks, and the latest data shows it delayed disease progression by more than a year. It is one of the company’s main new drug hopes, with AstraZeneca estimating that it could sell up to $ 3bn a year. It wants to bring six new cancer medicines to patients by 2020.

Continue reading…
Pharmaceuticals industry | The Guardian

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us